Welcome to our dedicated page for Xenon Pharmaceuticals SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Xenon Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Xenon Pharmaceuticals's regulatory disclosures and financial reporting.
Xenon Pharmaceuticals Inc. Chief Legal Officer Andrea DiFabio reported new equity awards. On January 9, 2026, DiFabio received share options covering 80,000 common shares at an exercise price of $42.15 per share, with no purchase price for the grant itself. These options vest 25% on January 9, 2027, with the remaining 75% vesting in equal monthly installments over the following three years.
On the same date, DiFabio was also granted 15,000 restricted share units, each representing a contingent right to receive one common share. These RSUs vest 25% on each of the first four anniversaries of the grant date, beginning January 9, 2027. Both awards are reported as directly held derivative securities.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported new equity awards. On January 9, 2026, he received a stock option for 350,000 common shares at an exercise price of $42.15 per share. This option vests 25% on January 9, 2027, with the remaining 75% vesting in equal monthly installments over the following three years.
He also received 65,000 restricted share units, each representing a contingent right to receive one common share. These restricted share units vest 25% on each of the first four anniversaries of the grant date, beginning January 9, 2027. Both the option and the restricted share units are reported as directly owned.
Xenon Pharmaceuticals Inc.’s president and CEO, who is also a director, reported open-market sales of company common shares under a Rule 10b5-1 trading plan. On 12/05/2025 the insider sold 14,375 common shares at a weighted-average price of $45.03 per share. On 12/08/2025 additional trades involved 8,820 shares at a weighted-average $45.59 and 2,010 shares at a weighted-average $46.32, each executed in multiple transactions within stated price ranges. Following these sales, the insider beneficially owns 6,000 common shares directly and 14,300 common shares indirectly through a spouse; the Rule 10b5-1 trading plan was adopted on September 27, 2024.
Xenon Pharmaceuticals (XENE) reported Q3 2025 results with a net loss of $90.9 million (basic and diluted loss per share $1.15). The quarter had no collaboration revenue; year-to-date revenue was $7.5 million from a Neurocrine milestone tied to NBI-921355 entering a Phase 1 study.
Operating expenses rose as late-stage programs advanced: R&D was $77.1 million and G&A was $19.3 million in Q3. Interest income was $6.2 million. Cash, cash equivalents and marketable securities totaled $555.3 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. Net cash used in operations for the first nine months was $197.6 million.
Pipeline updates: the Phase 3 X‑TOLE2 study in focal onset seizures completed enrollment (380 randomized) with topline data anticipated in early 2026; Phase 3 X‑TOLE3 (FOS) and X‑ACKT (PGTCS) continue. Phase 3 programs in MDD (X‑NOVA2/3) and bipolar depression (X‑CEED) are underway. Early-stage pain candidates include XEN1701 (Nav1.7) and XEN1120 (Kv7) in Phase 1.
Xenon Pharmaceuticals (XENE) furnished an update on its latest results. The company announced financial results for the three and nine months ended September 30, 2025 via a press release attached as Exhibit 99.1. The information under Item 2.02 and the exhibit are furnished, not filed with the SEC.
Xenon also notes it shares material updates through SEC filings, press releases, conference calls, its websites, and official social media channels.
Xenon Pharmaceuticals (XENE) filed a Form 4 reporting new equity awards to its Chief Financial Officer. On 10/15/2025, the officer received a stock option for 225,000 common shares at an exercise price of $41.9, expiring on 10/14/2035. The option vests 25% on October 15, 2026, with the remaining 75% vesting in equal monthly installments over the next three years.
The filing also reports 30,000 restricted share units (RSUs), vesting 25% on each of the first four anniversaries of the grant date, beginning October 15, 2026. The awards are reported as direct ownership.
Xenon Pharmaceuticals (XENE) filed a Form 3 initial ownership report. The reporting person is an officer serving as Chief Financial Officer and indicated no securities are beneficially owned (0) and no derivative securities are held. The stated date of event is 10/15/2025. The filing reflects an individual submission by one reporting person.
Xenon Pharmaceuticals (XENE) appointed Thomas (Tucker) Kelly as Chief Financial Officer, effective October 15, 2025. He becomes the company’s principal financial and accounting officer, bringing prior CFO experience at Deciphera Pharmaceuticals and earlier roles across life sciences finance, banking, and law.
Under his employment terms, Mr. Kelly will receive a $540,000 annual base salary and is eligible for an annual incentive of up to 45% of base salary. He will receive a one-time grant of 225,000 options and 30,000 RSUs under the 2025 Inducement Equity Incentive Plan. Severance terms include up to 18 months of base salary depending on tenure, pro-rated Average Bonus, retirement contribution equivalents for the severance period, and equity vesting and exercisability provisions, with enhanced benefits upon a qualifying termination during a change of control period. Ian Mortimer ceases interim CFO duties and continues as President and CEO.
Xenon Pharmaceuticals appointed Thomas (Tucker) Kelly as Chief Financial Officer, effective October 15, 2025. He becomes the company’s principal financial and accounting officer, bringing prior CFO experience from Deciphera Pharmaceuticals and earlier leadership roles across life sciences finance and banking. Ian Mortimer will cease serving as interim CFO and continues as President and CEO.
Kelly’s employment terms include a $540,000 annual base salary, an annual incentive opportunity up to 45% of base salary, a one-time grant of 225,000 stock options, and 30,000 RSUs under the 2025 Inducement Plan. If terminated without cause outside a change of control period, severance equals 12 months of base salary plus one month per year of service (capped at 18 months), pro‑rated Average Bonus, retirement contributions for the severance period, and limited continued vesting and exercisability. During a change of control period, severance includes 100% target bonus, full vesting acceleration, and extended exercisability as outlined.
Xenon Pharmaceuticals insider transactions by Ian Mortimer show the reporting person exercised a fully vested option to buy 25,000 common shares at $7.69 and simultaneously sold 25,000 shares under a prearranged Rule 10b5-1 plan on 10/01/2025. The sale proceeds reflect an aggregate weighted-average price of $40.16 per share (individual sales ranged $40.00 to $40.495). After these transactions Mortimer directly beneficially owned 31,302 shares and indirectly owned 14,300 shares through his spouse, totaling 45,602 shares. The filing states the option exercised is fully vested and exercisable and that the sales were executed under a 10b5-1 plan.